| Clostridium Difficile Infection |
1 |
1 |
| Biologic Therapy |
0 |
0.96 |
| Clinical Guidelines |
0 |
0.92 |
| Microbiome |
0 |
0.79 |
| Revenue and Practice Management |
0 |
0.44 |
| Fecal Transplant |
0 |
0.33 |
| Antibiotics |
0 |
0.32 |
| Heart Failure (HF) |
0 |
0.23 |
| Social Determinants of Health |
0 |
0.22 |
| Hospital |
0 |
0.15 |
| Cardiomyopathy |
0 |
0.14 |
| COVID-19 |
0 |
0.11 |
| Health Care Quality, Access, and Evaluation |
0 |
0.1 |
| Illinois |
0 |
0.1 |
| Monoclonal Antibody |
0 |
0.1 |
| Heart Transplantation |
0 |
0.07 |
| Society for Healthcare Epidemiology of America |
0 |
0.07 |
| Epidemiology |
0 |
0.05 |
| Financial Reimbursement |
0 |
0.05 |
| Food and Drug Administration (FDA) |
0 |
0.05 |
| Heart |
0 |
0.05 |
| Imbalance |
0 |
0.05 |
| Indiana |
0 |
0.05 |
| Insurance |
0 |
0.05 |
| Prophylaxis |
0 |
0.05 |
| Transplantation |
0 |
0.05 |
| Virginia |
0 |
0.05 |